LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

31.24 0.13

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

31.21

Massimo

31.24

Metriche Chiave
By Trading Economics
Entrata	11M 64M
Vendite	-3.2M 149M
P/E Media del settore	18.052 49.701
EPS	0.79
Margine di Profitto	42.663
Dipendenti	182
EBITDA	2M 83M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+6.06% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	281M 3.8B
Apertura precedente	31.11
Chiusura precedente	31.24

Notizie sul Sentiment di mercato

By Acuity

50%

159 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

N/A / 24.28 Supporto e resistenza

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 mag 2026, 23:31 UTC

Azioni calde

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mag 2026, 22:52 UTC

I principali Market Mover

Osisko Shares Fall on Planned Convertible Notes Offering

20 mag 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mag 2026, 23:44 UTC

Utili

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mag 2026, 23:35 UTC

Discorsi di Mercato

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mag 2026, 23:30 UTC

Discorsi di Mercato

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mag 2026, 23:17 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 mag 2026, 23:17 UTC

Discorsi di Mercato

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mag 2026, 23:15 UTC

Discorsi di Mercato

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mag 2026, 23:14 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mag 2026, 23:02 UTC

Discorsi di Mercato

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 mag 2026, 22:51 UTC

Discorsi di Mercato

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mag 2026, 22:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 mag 2026, 22:27 UTC

Discorsi di Mercato

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mag 2026, 22:14 UTC

Discorsi di Mercato

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mag 2026, 22:10 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mag 2026, 22:00 UTC

Utili

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mag 2026, 21:38 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mag 2026, 21:27 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mag 2026, 21:20 UTC

Utili

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mag 2026, 21:19 UTC

Utili

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mag 2026, 21:18 UTC

Utili

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mag 2026, 21:17 UTC

Utili

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mag 2026, 21:17 UTC

Utili

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mag 2026, 21:17 UTC

Utili

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mag 2026, 21:16 UTC

Utili

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

6.06% in crescita

Previsioni per 12 mesi

Media 33.1 USD 6.06%

Alto 35 USD

Basso 31.5 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

159 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.